Author

N. T. Ryujin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Assay:multiome· 1 Organism:non-human primate· 1

Frequent Co-Authors

S. Shalapour· 2 shared A. Nguyen· 1 shared A. O. Kaseb· 1 shared D. P. Dowlatshahi· 1 shared H. Sugimoto· 1 shared J. Dai· 1 shared J. H. Simmons· 1 shared J. Hensel· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

S. Shalapour

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity

X. Luo, K. M. McAndrews, K. A. Arian, S. J. Morse, V. Boeker, S. V. Kumbhar, Y. Hu, K. K. Mahadevan, K. A. Church, S. Chitta, N. T. Ryujin, J. Hensel, J. Dai, D. P. Dowlatshahi, H. Sugimoto, , R. Kalluri

This paper develops an engineered extracellular vesicles-based vaccine platform for combined mRNA and protein delivery, showing tumor regression and immune responses in preclinical models.

bioRxiv · Mar 14, 2024Immunology

Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells

L. Gu, Y. Zhu, M. Lee, A. Nguyen, N. T. Ryujin, J. Huang, S. Chamseddine, L. Xiao, Y. I. Mohamed, A. O. Kaseb, M. Karin, S. Shalapour

This study shows that losartan, an angiotensin II receptor inhibitor, reduces liver fibrosis and enhances T cell infiltration in HCC, improving response to PD-1 blockade.

bioRxiv · Mar 5, 2023 · PreprintCancer Biology